Universitätsklinikum Hamburg-Eppendorf
uke.deTotal trials
408
Active
87
Phase 3
21
Total enrollment
3,306,514
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 21 of 21 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Esomeprazole 20mg | — | — | — | — | — | 1 | |
| Capecitabine | — | — | — | — | 2 | ||
| ERVEBO® | — | — | — | — | — | 1 | |
| Reduced-intensity maintenance chemotherapy | — | — | — | — | — | 1 | |
| Maintenance chemotherapy | — | — | — | — | — | 1 | |
| Induction Chemotherapy | — | — | — | — | — | 1 | |
| Vinblastin Maintenance | — | — | — | — | — | 1 | |
| Gemcitabine | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | 2 | ||
| Isatuximab | — | — | — | — | — | 2 | |
| Belantamab mafodotin, Venetoclax | — | — | — | — | — | 1 | |
| Uvadex | — | — | — | — | — | 1 | |
| Carfilzomib | — | — | — | — | — | 1 | |
| Lenalidomide | — | — | — | — | — | 1 | |
| Ruxolitinib continuous therapy | — | — | — | — | — | 1 | |
| Allogeneic Stem Cell Transplantation | — | — | — | — | — | 1 | |
| Etentamig | — | — | — | — | — | 1 | |
| Bortezomib + Lenalidomide + Dexamethasone | — | — | — | — | — | 1 | |
| Dexamethasone | — | — | — | 4 | |||
| HEPLISAV B; TherVacB | — | — | — | — | — | 1 | |
| TherVacB | — | — | — | — | — | 1 |
Next readouts
- 2024-06-24
- 2024-10-07
- 2025-12
- 2026-02
- 2026-05
- 2026-11-22
- 2026-12
- 2027-04
- 2027-12
- 2028-02
Top conditions
- Airway Management14
- Stroke14
- Depression11
- Schizophrenia10
- Multiple Myeloma9
- Anesthesia9
- Atrial Fibrillation8
- Multiple Sclerosis8
Frequently asked questions about Universitätsklinikum Hamburg-Eppendorf
- How many clinical trials does Universitätsklinikum Hamburg-Eppendorf have on ClinicalTrials.gov?
- Universitätsklinikum Hamburg-Eppendorf is listed as the lead sponsor on 408 clinical trials in ClinicalTrials.gov, 87 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Universitätsklinikum Hamburg-Eppendorf's trials are in Phase 3?
- 21 of Universitätsklinikum Hamburg-Eppendorf's trials are in Phase 3, spread across 21 active drug programs.
- What therapeutic areas does Universitätsklinikum Hamburg-Eppendorf focus on?
- Universitätsklinikum Hamburg-Eppendorf's most-studied conditions on ClinicalTrials.gov are Airway Management, Stroke, Depression, Schizophrenia, Multiple Myeloma.
- When are Universitätsklinikum Hamburg-Eppendorf's next clinical trial readouts?
- Universitätsklinikum Hamburg-Eppendorf has 10 upcoming primary-completion readouts tracked here; the soonest is “Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease”, expected around 2024-06-24.